Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
Abstract
Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin. The combination of insulin detemir (insulin analogue) with liraglutide (GLP-1 analogue) reduces fasting and postprandial glycaemia, lowers the risk of hypoglycaemia and does not have a negative impact on body weight. In this literature review, the pharmacodynamic and pharmacokinetic profiles, as well as the potential benefits of combined insulin detemir and liraglutide therapy on diabetic nephropathy and high cardiovascular disease risk were determined. Data from randomised clinical trials and the National Registry were used to assess the clinical efficacy of combined insulin detemir and liraglutide therapy. The different mechanistic actions of insulin detemir and liraglutide resulted in an additive glucose-lowering effect, which did not affect the pharmacodynamic and pharmacokinetic profiles of each therapeutic agent.
About the Authors
Lyudmila Alexandrovna RuyatkinaNovosibirsk state medical university
Russian Federation
MD, PhD, Professor
Competing Interests:
Чтение лекций, участие в советах, клинических исследованиях, консультационные услуги компаниям: Ново Нордиск, Санофи, Лилли, Такеда, Берингер, Астра Зенека, Берлин-Хеми, Мерк, Промомед, Эбботт.
Maxim Sorokin
City Clinical Hospital No1
Russian Federation
MD
Competing Interests:
Участие в клинических исследованиях, спонсируемых компаниями Ново Нордиск, Санофи, Берингер, Байер.
References
1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi: 10.2337/dc14-2441
2. Дедов И.И., Шестакова М.В., Аметов А.С., и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа // Сахарный диабет. – 2011. – Т. 14. – №4. – C. 6-17. [Dedov II, Shestakova MV, Ametov AS, et al. Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapyin type 2 diabetes mellitus. Diabetes mellitus. 2011;14(4):6-17. (in Russ)] doi: 10.14341/2072-0351-5810
3. Grams J, Garvey WT. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep. 2015;4(2):287-302. doi: 10.1007/s13679-015-0155-x
4. Garvey WT, Garber AJ, Mechanick JI, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977-989. doi: 10.4158/EP14280.PS
5. Левит Ш., Филиппов Ю.И., Горелышев А.С. Сахарный диабет 2 типа: время изменить концепцию // Сахарный диабет. – 2013. – Т. 16. – №1. – C. 91-102. [Levit S, Filippov YI, Gorelyshev AS. Type 2 diabetes mellitus: time to change the concept. Diabetes mellitus. 2013;16(1):91-102. (in Russ)] doi: 10.14341/2072-0351-3603
6. Arbeeny CM. Addressing the unmet medical need for safe and effective weight loss therapies. Obes Res. 2004;12(8):1191-1196. doi: 10.1038/oby.2004.150
7. Дедов И.И., Шестакова М.В., Абусуев С.А., и др. Оптимизация и интенсификация инсулинотерапии при сахарном диабете 2 типа (клинические рекомендации) // Сахарный диабет. – 2010. – Т. 13. – №5. – C. 9-16. [Dedov II, Shestakova MV, Abusuev SA, Valeeva FV, Verbovoy AF, Galstyan GR, et al. Optimizatsiya i intensifikatsiya insulinoterapii pri sakharnom diabete 2 tipa (klinicheskie rekomendatsii). Diabetes mellitus. 2010;13(5):9-16. (in Russ)] doi: 10.14341/2072-0351-6049
8. Vora J. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care. 2013;36 Suppl 2:S226-232. doi: 10.2337/dcS13-2036
9. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716-1730. doi: 10.1056/NEJMoa075392
10. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408-416. doi: 10.1007/s00125-007-0911-x
11. Ahren B. Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes. 2009;58(3):726-731. doi: 10.2337/db08-1158
12. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.. 1997;273(5):E981-E988.
13. Gutzwiller J-P, Drewe J, Göke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276(5):R1541-R1544.
14. Joly E, Prentki M, Buteau J, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004;47(5):806-815. doi: 10.1007/s00125-004-1379-6
15. Ahrén B. Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. EurDiabet Nursing. 2013;10(1):31-36. doi: 10.1002/edn.221
16. Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi: 10.1021/acs.jmedchem.5b00726
17. Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514. doi: 10.2337/dc11-0632
18. Gonzalez-Sanchez JL, Serrano-Rios M. Molecular basis of insulin action. Drug News Perspect. 2007;20(8):527-531. doi: 10.1358/dnp.2007.20.8.1157615
19. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005;48(9):1700-1713. doi: 10.1007/s00125-005-1878-0
20. Holt P. Diabetes in hospital: a practical approach for healthcare professionals. John Wiley & Sons; 2009. doi: 10.1002/9780470749746
21. Ahren B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33(4):730-732. doi: 10.2337/dc09-1867
22. Seghieri M, Rebelos E, Gastaldelli A, et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia. 2013;56(1):156-161. doi: 10.1007/s00125-012-2738-3
23. Lorenz M, Pfeiffer C, Steinstrasser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. Regul Pept. 2013;185:1-8. doi: 10.1016/j.regpep.2013.04.001
24. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565. doi: 10.2337/db10-0474
25. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. The Lancet. 2008;372(9645):1240-1250. doi: 10.1016/s0140-6736(08)61206-4
26. Jelsing J, Vrang N, Hansen G, et al. Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight. Diabetes Obes Metab. 2012;14(6):531-538. doi: 10.1111/j.1463-1326.2012.01557.x
27. Vella A, Bock G, Giesler PD, et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf). 2008;69(5):737-744. doi: 10.1111/j.1365-2265.2008.03235.x
28. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(5):2078-2084. doi: 10.1210/jc.2003-031907
29. Ahren B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag. 2013;9:155-163. doi: 10.2147/VHRM.S33934
30. Руяткина Л.А., Руяткин Д.С., Березовская Г.А. К вопросу о приоритетах сахароснижающей терапии сахарного диабета 2 типа: сердечно-сосудистые аспекты гипогликемий. // Сердце. – 2013. – №4. – С. 207-213. [Ruyatkina LA, Watkin DS, Berezovskaya GA. To the question about the priorities of hypoglycemic therapy of diabetes mellitus type 2: cardiovascular aspects of hypoglycemia. Heart. 2013;4:207-213 (in Russ)].
31. Ahrén B, Farngren J, Persson M, et al. Improved glucagon dynamics during hypoglycaemia and food-rechallenge by DPP-4 inhibition by vildagliptin in insulin-treated patients with type 2 diabetes. Diabetologia. 2013;56suppl 1:S51–S52
32. Bagg W, Plank LD, Gamble G, et al. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. DiabetesObesMetab. 2001;3(6):410-416. doi: 10.1046/j.1463-1326.2001.00153.x
33. Strachan MW, Ewing FM, Frier BM, et al. Food cravings during acute hypoglycaemia in adults with Type 1 diabetes. Physiol Behav. 2004;80(5):675-682. doi: 10.1016/j.physbeh.2003.12.003
34. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep. 2001;2(4):282-286. doi: 10.1093/embo-reports/kve071
35. Schwartz MW, Woods SC, Porte D, et al. Central nervous system control of food intake. Nature. 2000;404(6778):661-671.
36. Ryan M, Livingstone MBE, Ducluzeau PH, et al. Is a Failure to Recognize an Increase in Food Intake a Key to Understanding Insulin-Induced Weight Gain? Diabetes Care. 2007;31(3):448-450. doi: 10.2337/dc07-1171
37. Руяткина Л.А., Сорокин М.Ю. Детемир (Левемир): современные парадигмы инсулинотерапии // Проблемы Эндокринологии. – 2013. – Т. 59. – №4. – C. 56-64. [Ruiatkina LA, Sorokin MI. Detemir (Levemir): modern paradigms of insulin therapy. Problems of Endocrinology. 2013;59(4):56-64. (in Russ)] doi: 10.14341/probl201359456-64
38. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771
39. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187-218. doi: 10.1210/10.1210/er.2006-0038
40. Kondo Y, Satoh S, Osada UN, Terauchi Y. Early liraglutide treatment improves beta-cell function in patients with type 2 diabetes: a retrospective cohort study. Endocr J. 2015;62(11):971-980. doi: 10.1507/endocrj.EJ15-0206
41. Retnakaran R, Kramer CK, Choi H, et al. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care. 2014;37(12):3270-3278. doi: 10.2337/dc14-0893
42. Raz I, Mosenzon O. Early insulinization to prevent diabetes progression. Diabetes Care. 2013;36 Suppl 2:S190-197. doi: 10.2337/dcS13-2014
43. Funch D, Gydesen H, Tornoe K, et al. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab. 2014;16(3):273-275. doi: 10.1111/dom.12230
44. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96(6):1695-1702. doi: 10.1210/jc.2010-2822
45. Schweizer A, Dejager S, Foley JE, et al. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12(6):485-494. doi: 10.1111/j.1463-1326.2010.01215.x
46. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271-284. doi: 10.1016/j.diabres.2012.09.008
47. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-1486. doi: 10.1210/en.2009-1272
48. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab. 2011;96(7):2027-2031. doi: 10.1210/jc.2011-0599
49. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112-120. doi: 10.1111/dom.12000
50. Monami M, Dicembrini I, Nardini C, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(1):38-47. doi: 10.1111/dom.12175
51. Руяткина Л.А., Руяткин Д.С., Овсянникова А.К. К вопросу о контроле углеводного обмена при остром коронарном синдроме с диcгликемией. // Сердце: журнал для практикующих врачей. – 2016. – Т. 15. – №4. – С. 265–271 [Ruyatkina L A, Watkin DS, Ovsyannikova A K. To the question of the control of carbohydrate metabolism in acute coronary syndrome with dysglycemia. Heart: journal for practitioners. 2016;15(4):265-271 (in Russ)]
52. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011;108(3 Suppl):33B-41B. doi: 10.1016/j.amjcard.2011.03.046
53. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: 10.1056/NEJMoa1603827
54. Chen WR, Shen XQ, Zhang Y, et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016;52(3):516-526. doi: 10.1007/s12020-015-0798-0
55. Chen WR, Tian F, Chen YD, et al. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol. 2016;208:109-114. doi: 10.1016/j.ijcard.2015.12.009
56. Liu M, Shen Y, Chen C, et al. Protective effect of glucagon-like peptide-1 analogue on cardiomyocytes injury induced by hypoxia/reoxygenation. ZhonghuaNeiKeZaZhi. 2016;55(4):311-316.
57. Wang X, Ding Z, Yang F, et al. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together. Clinl Sci. 2016;130(15):1353-1362. doi: 10.1042/cs20160061
58. Hanefeld M, Monnier L, Schnell O, Owens D. Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Ther. 2016;7(2):187-201. doi: 10.1007/s13300-016-0153-3
59. Price HI, Agnew MD, Gamble JM. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. BMJ Open. 2015;5(3):e006341. doi: 10.1136/bmjopen-2014-006341
60. Strandberg AY, Hoti FJ, Strandberg TE, et al. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine. PLoS One. 2016;11(3):e0151910. doi: 10.1371/journal.pone.0151910
61. Makino H, Tanaka A, Hosoda H, et al. Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes. Diabet Med. 2016;33(12):1737-1743. doi: 10.1111/dme.13151
62. Wu JW, Filion KB, Azoulay L, et al. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. Diabetes Care. 2016;39(3):486-494. doi: 10.2337/dc15-1816
63. Buturovic BA, Ristic LB, Narancic AM. Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. Med Arch. 2014;68(5):313-316. doi: 10.5455/medarh.2014.68.313-316
64. Zinman B, Gerich J, Buse J, et al. American Diabetes Association. Standards of medical care in diabetes-2010 (vol 33, pg S11, 2010). Diabetes care. 2010;33(3):692-692.
65. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. British Journal of Clinical Pharmacology. 2009;68(6):898-905. doi: 10.1111/j.1365-2125.2009.03536.x
66. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222-230.
67. Rosenstock J, Rodbard HW, Bain SC, et al. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications. 2013;27(5):492-500. doi: 10.1016/j.jdiacomp.2013.04.008
68. Morrow L, Hompesch M, Guthrie H, et al. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab. 2011;13(1):75-80. doi: 10.1111/j.1463-1326.2010.01322.x
69. Ahmann A, Rodbard HW, Rosenstock J, et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2015;17(11):1056-1064. doi: 10.1111/dom.12539
70. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2012;6(1):41-46. doi: 10.1016/j.pcd.2011.09.002
71. Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014;16(7):636-644. doi: 10.1111/dom.12262
72. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther. 2011;13(5):592-595. doi: 10.1089/dia.2010.0221
73. John M, Gopinath D, Jagesh R. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives. Indian J Endocrinol Metab. 2016;20(1):22-31. doi: 10.4103/2230-8210.172268
74. Gurgle HE, White K, McAdam-Marx C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. VascHealthRiskManag. 2016;12:239.
75. Ahrén B. Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. World J Diabetes. 2014;5(1):40. doi: 10.4239/wjd.v5.i1.40
76. Пашкова Е.И. Новые терапевтические возможности в лечении сахарного диабета 2-го типа: добавление к лираглутиду инсулина детемир // Проблемы Эндокринологии. – 2013. – Т. 59. – №4. – C. 50-55. [Pashkova EI. The new therapeutic modalities for the treatment of type 2 diabetes mellitus: insulin detemir added to liraglutide. Problems of Endocrinology. 2013;59(4):50-55. (in Russ)] doi: 10.14341/probl201359450-55.
Supplementary files
|
|
1. Рис. 1. Выживаемость больных СД2 при использовании различных препаратов базального инсулина [61]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(97KB)
|
Indexing metadata ▾ | |
|
|
2. Рис. 2. Динамика СКФ у пациентов с СД2 и ХБП С3 в течение 26 недель при терапии лираглутидом в сравнении с плацебо [67]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(97KB)
|
Indexing metadata ▾ | |
|
|
3. Рис. 3. Иллюстрация аддитивного эффекта при использовании комбинации детемира и лираглутида [68]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(187KB)
|
Indexing metadata ▾ | |
Review
For citations:
Ruyatkina L.A., Sorokin M. Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance. Diabetes mellitus. 2017;20(2):142-150. (In Russ.) https://doi.org/10.14341/7875
Views:
907
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
